Galectins as potential pharmacological targets in renal injuries of diverse etiology.
Diabetes
Galectins
Glomerulus
Injury
Kidney
Nephropathy
Journal
European journal of pharmacology
ISSN: 1879-0712
Titre abrégé: Eur J Pharmacol
Pays: Netherlands
ID NLM: 1254354
Informations de publication
Date de publication:
15 Aug 2020
15 Aug 2020
Historique:
received:
07
02
2020
revised:
14
05
2020
accepted:
19
05
2020
pubmed:
26
5
2020
medline:
11
5
2021
entrez:
26
5
2020
Statut:
ppublish
Résumé
Galectins are carbohydrate-binding proteins, and their importance in renal diseases of diverse etiology has been documented. Amongst different galectins, the role of galectin-3 in the pathophysiology of renal diseases has been well documented. There is an increase in galectin-3 in the circulation as well as on the kidneys in chronic kidney disease patients. The increase in galectin-3 is negatively correlated with a decrease in renal function and overall survival rate. The preclinical studies also correlate the increase in galectin-3 levels with renal dysfunction. Accordingly, scientists have exploited galectin-3 as a potential pharmacological target to improve renal functions in different preclinical models of renal injury. Apart from galectin-3, there have been few studies documenting the role of galectin-1, 8, and 9 in renal diseases. The role of galectin-1 is not clearly identified, and there have been conflicting reports regarding its role in renal diseases. Galectin-8 and 9 impart renoprotective effects as per clinical and preclinical studies, respectively. The present review discusses the role of different galectins in renal diseases of diverse etiology.
Identifiants
pubmed: 32450176
pii: S0014-2999(20)30305-8
doi: 10.1016/j.ejphar.2020.173213
pii:
doi:
Substances chimiques
Galectins
0
Renal Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
173213Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.